title: Targeting pathological B cell receptor signalling in lymphoid malignancies.
abstract: Signalling through the B cell receptor (BCR) is central to the development and maintenance of B cells. In light of the numerous proliferative and survival pathways activated downstream of the BCR, it comes as no surprise that malignant B cells would co-opt this receptor to promote their own growth and survival. However, direct evidence for BCR signalling in human lymphoma has only come to light recently. Roles for antigen-dependent and antigen-independent, or tonic, BCR signalling have now been described for several different lymphoma subtypes. Furthermore, correlative data implicate antigen-dependent BCR signalling in many other forms of lymphoma. A host of therapeutic agents targeting effectors of the BCR signalling pathway are now in clinical trials and have shown initial success against multiple forms of lymphoma.
authors: Metabolism Branch, Center for Cancer Research, National Cancer Institute, US National Institutes of Health, Bethesda, Maryland 20892, USA.
authors: Ryan M
authors: RM
authors: Young
authors: Louis M
authors: LM
authors: Staudt
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000502:physiology; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects / Q000502:physiology; D008223:Lymphoma / Q000188:drug therapy / Q000503:physiopathology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000502:physiology; D011947:Receptors, Antigen, B-Cell / Q000187:drug effects / Q000502:physiology*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*
chemical_list: D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D011947:Receptors, Antigen, B-Cell; D011505:Protein-Tyrosine Kinases